These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36679847)

  • 1. A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines.
    Goksøyr L; Skrzypczak M; Sampson M; Nielsen MA; Salanti A; Theander TG; Remaley AT; De Jongh WA; Sander AF
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
    Martinez FG; Zielke RA; Fougeroux CE; Li L; Sander AF; Sikora AE
    Infect Immun; 2023 Dec; 91(12):e0024523. PubMed ID: 37916806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
    Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.
    Fausch SC; Da Silva DM; Kast WM
    Vaccine; 2005 Feb; 23(14):1720-9. PubMed ID: 15705478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.
    Momtazi-Borojeni AA; Jaafari MR; Badiee A; Sahebkar A
    Atherosclerosis; 2019 Apr; 283():69-78. PubMed ID: 30797988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cholesterol-lowering VLP vaccine that targets PCSK9.
    Crossey E; Amar MJA; Sampson M; Peabody J; Schiller JT; Chackerian B; Remaley AT
    Vaccine; 2015 Oct; 33(43):5747-5755. PubMed ID: 26413878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers.
    Prentoe J; Janitzek CM; Velázquez-Moctezuma R; Soerensen A; Jørgensen T; Clemmensen S; Soroka V; Thrane S; Theander T; Nielsen MA; Salanti A; Bukh J; Sander AF
    NPJ Vaccines; 2022 Nov; 7(1):148. PubMed ID: 36379958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Purification of Tag/Catcher AP205-Based Capsid Virus-Like Particle Vaccines.
    Aves KL; Sander AF
    Methods Mol Biol; 2024; 2720():127-141. PubMed ID: 37775662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Therapeutic Peptide Vaccine Against PCSK9.
    Pan Y; Zhou Y; Wu H; Chen X; Hu X; Zhang H; Zhou Z; Qiu Z; Liao Y
    Sci Rep; 2017 Oct; 7(1):12534. PubMed ID: 28970592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9.
    Chackerian B; Remaley A
    Curr Opin Lipidol; 2016 Aug; 27(4):345-50. PubMed ID: 27389630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Display of Streptococcus iniae α-Enolase on the Surface of Virus-Like Particles (VLPs) of Nervous Necrosis Virus (NNV) Using SpyTag/SpyCatcher.
    Yang JI; Kim KH
    Mar Biotechnol (NY); 2022 Dec; 24(6):1066-1072. PubMed ID: 36171522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
    Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
    Heinimäki S; Lampinen V; Tamminen K; Hankaniemi MM; Malm M; Hytönen VP; Blazevic V
    Virology; 2022 Jan; 566():89-97. PubMed ID: 34894525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-dose, implant-based, trivalent virus-like particle vaccine against "cholesterol checkpoint" proteins.
    Ortega-Rivera OA; Pokorski JK; Steinmetz NF
    Adv Ther (Weinh); 2021 Aug; 4(8):. PubMed ID: 34541299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
    Galabova G; Brunner S; Winsauer G; Juno C; Wanko B; Mairhofer A; Lührs P; Schneeberger A; von Bonin A; Mattner F; Schmidt W; Staffler G
    PLoS One; 2014; 9(12):e114469. PubMed ID: 25474576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis.
    Goksøyr L; Funch AB; Okholm AK; Theander TG; de Jongh WA; Bonefeld CM; Sander AF
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.